82_FR_10807 82 FR 10777 - National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations

82 FR 10777 - National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 30 (February 15, 2017)

Page Range10777-10778
FR Document2017-03018

The Office of the Secretary of the Department of Health and Human Services (HHS) is seeking nominations for an individual to serve as a nonfederal public member on the Muscular Dystrophy Coordinating Committee.

Federal Register, Volume 82 Issue 30 (Wednesday, February 15, 2017) 
[Federal Register Volume 82, Number 30 (Wednesday, February 15, 2017)]
[Notices]
[Pages 10777-10778]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-03018]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Neurological Disorders and Stroke, Muscular 
Dystrophy Coordinating Committee Call for Committee Membership 
Nominations

SUMMARY: The Office of the Secretary of the Department of Health and 
Human Services (HHS) is seeking nominations for an individual to serve 
as a nonfederal public member on the Muscular Dystrophy Coordinating 
Committee.

DATES: Nominations are due by 5 p.m. EST on March 17, 2017.

ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email 
to [email protected].

FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to 
[email protected].

SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating 
Committee (MDCC) is a federal advisory committee established in 
accordance with the Muscular Dystrophy Community Assistance, Research, 
and Education Amendments of 2001 (MD-CARE Act; Pub. L. 107-84). The MD-
CARE Act was reauthorized in 2008 by Pub. L. 110-361, and again in 2014 
by Pub. L. 113-166. The MD-CARE Act specifies that the committee 
membership be composed of 2/3 governmental agency representatives and 
1/3 public members. We are seeking nominations for four non-federal, 
public members at this time, due to turnover of committee membership. 
Nominations will be accepted between February 17 and March 17, 2017.
    Who is Eligible: Nominations are encouraged for new or 
reappointment of non-federal public members who can provide the public 
and/or patient perspectives to discussions of issues considered by the 
Committee. Self-nominations and nominations of other individuals are 
both permitted. Only one nomination per individual is required. 
Multiple nominations for the same individual will not increase 
likelihood of selection. Non-federal, public members may be selected 
from the pool of submitted nominations or other sources as needed to 
meet statutory requirements and to form a balanced committee that 
represents the diversity within the muscular dystrophy communities. 
Nominations are especially encouraged from leaders or representatives 
of muscular dystrophy research, advocacy, or service organizations, 
individuals with muscular dystrophy or their parents or guardians. In 
accordance with White House Office of Management and Budget guidelines 
(FR Doc. 2014- 19140), federally-registered lobbyists are not eligible.
    Committee Composition: The Department strives to ensure that the 
membership of HHS Federal advisory committees is fairly balanced in 
terms of points of view represented and the committee's function. Every 
effort is made to ensure that the views of all genders, all ethnic and 
racial groups, and people with disabilities are represented on HHS 
Federal advisory committees and, therefore, the Department encourages 
nominations of qualified candidates from these groups. The Department 
also encourages geographic diversity in the composition of the 
Committee. Appointment to this

[[Page 10778]]

Committee shall be made without discrimination on the basis of age, 
race, ethnicity, gender, sexual orientation, disability, and cultural, 
religious, or socioeconomic status. Requests for reasonable 
accommodation to enable participation on the Committee should be 
indicated in the nomination submission.
    Member Terms: Non-Federal public members of the Committee serve for 
a term of 3 years, and may serve for an unlimited number of terms if 
reappointed. Members may serve after the expiration of their terms, 
until their successors have taken office.
    Meetings and Travel: As specified by Pub. L. 113-166, the MDCC 
``shall meet no fewer than two times per calendar year.'' Travel 
expenses are provided for non-federal public Committee members to 
facilitate attendance at in-person meetings. Members are expected to 
make every effort to attend all full committee meetings, twice per 
year, either in person or via remote access. Participation in relevant 
subcommittee, working and planning group meetings, and workshops, is 
also encouraged.
    Submission Instructions and Deadline: Nominations are due by 5 p.m. 
EST on March 17, 2017, and should be sent to Glen Nuckolls, Ph.D., by 
email to [email protected].
    Nominations must include contact information for the nominee, a 
current curriculum vitae or resume of the nominee and a paragraph 
describing the qualifications of the person to represent some 
portion(s) of the muscular dystrophy research, advocacy and/or patient 
care communities.
    More information about the MDCC is available at https://mdcc.nih.gov/.

     Dated: February 10, 2017.
Walter J. Koroshetz,
Director, National Institute of Neurological Disorders and Stroke, 
National Institutes of Health.
[FR Doc. 2017-03018 Filed 2-14-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices 10777 FOR FURTHER INFORMATION CONTACT: Sosnovtsev (NIAID), Marina Bok (EM), FOR FURTHER INFORMATION CONTACT: Glen Licensing information and copies of the Pamela Aguilar (EM), Lorena Nuckolls, Ph.D., by email to nuckollg@ patent applications listed below may be Garaicoechea (EM), and Viviana Parreno ninds.nih.gov. obtained by communicating with the (EM). SUPPLEMENTARY INFORMATION: The indicated licensing contact at the Publications: Garaicoechea L. et al., Muscular Dystrophy Coordinating Technology Transfer and Intellectual ‘‘Llama nanoantibodies with therapeutic Committee (MDCC) is a federal advisory Property Office, National Institute of potential against human norovirus committee established in accordance Allergy and Infectious Diseases, 5601 diarrhea,’’ PLoS One. 2015 Aug with the Muscular Dystrophy Fishers Lane, Rockville, MD 20852; tel. 12;10(8):e0133665. doi:10.1371/ Community Assistance, Research, and 301–496–2644. A signed Confidential journal.pone.0133665. eCollection 2015. Education Amendments of 2001 (MD– Disclosure Agreement will be required [PMID 26267898]. CARE Act; Pub. L. 107–84). The MD– to receive copies of unpublished patent Intellectual Property: HHS Reference CARE Act was reauthorized in 2008 by applications. No. E–136–2013/0—U.S. Provisional Pub. L. 110–361, and again in 2014 by SUPPLEMENTARY INFORMATION: Application No. 61/821,354, filed May Pub. L. 113–166. The MD–CARE Act Technology description follows. 9, 2013; PCT Application No. PCT/ specifies that the committee US2014/037520, filed May 9, 2014; Single-Chain Antibodies Directed to membership be composed of 2/3 European Application No. 14727696.8, Norovirus GI.1 and GII.4 and Their Use governmental agency representatives filed May 9, 2014 (pending); U.S. and 1/3 public members. We are seeking Description of Technology: Vaccines Application No. 14/889,774, filed nominations for four non-federal, public and therapies to prevent and treat November 6, 2015 (pending); and members at this time, due to turnover of Norovirus infections are not available, Argentine Application No. 20140101882, filed May 9, 2014 committee membership. Nominations despite the worldwide prevalence of will be accepted between February 17 Norovirus infections. Outbreaks of (pending). Licensing Contact: Peter Soukas, J.D., and March 17, 2017. human gastroenteritis attributable to Who is Eligible: Nominations are Norovirus commonly occur in group 301–594–8730; peter.soukas@nih.gov. Collaborative Research Opportunity: encouraged for new or reappointment of settings, such as hospitals, nursing non-federal public members who can homes, schools, dormitories, cruise The National Institute of Allergy and Infectious Diseases is seeking statements provide the public and/or patient ships and military barracks. This perspectives to discussions of issues application claims isolated VHH of capability or interest from parties interested in collaborative research to considered by the Committee. Self- monoclonal antibodies that specifically nominations and nominations of other bind to a Norovirus polypeptide. Llama- further develop, evaluate or commercialize for development of a individuals are both permitted. Only derived single chain antibody fragments one nomination per individual is (also called VHH) are small, therapeutic, diagnostic or vaccine for Norovirus infections. For collaboration required. Multiple nominations for the recombinant monoclonal antibodies of same individual will not increase 15 kDa (‘‘nanobodies’’) with several opportunities, please contact Peter Soukas, J.D., 301–594–8730; likelihood of selection. Non-federal, advantages over conventional public members may be selected from antibodies. The antibodies that were peter.soukas@nih.gov. the pool of submitted nominations or derived from llamas showed strong Dated: February 8, 2017. other sources as needed to meet neutralizing activity against Norovirus Suzanne Frisbie, statutory requirements and to form a in in vitro assays. These nanobodies Deputy Director, Technology Transfer and balanced committee that represents the may have application as Intellectual Property Office, National Institute diversity within the muscular dystrophy immunoprophylaxis to protect of Allergy and Infectious Diseases. communities. Nominations are individuals from infections or as a [FR Doc. 2017–03015 Filed 2–14–17; 8:45 am] especially encouraged from leaders or possible treatment for infected BILLING CODE 4140–01–P representatives of muscular dystrophy individuals, or can be used to develop research, advocacy, or service a diagnostic for detection of norovirus organizations, individuals with infections, and may be potentially DEPARTMENT OF HEALTH AND muscular dystrophy or their parents or utilized in vaccine research. HUMAN SERVICES guardians. In accordance with White This technology is available for House Office of Management and licensing for commercial development National Institutes of Health Budget guidelines (FR Doc. 2014– in accordance with 35 U.S.C. 209 and 37 19140), federally-registered lobbyists are National Institute of Neurological CFR part 404, as well as for further not eligible. Disorders and Stroke, Muscular development and evaluation under a Committee Composition: The Dystrophy Coordinating Committee research collaboration. Department strives to ensure that the Potential Commercial Applications: Call for Committee Membership Nominations membership of HHS Federal advisory • Therapeutics committees is fairly balanced in terms of • Diagnostics SUMMARY: The Office of the Secretary of • Vaccine research points of view represented and the the Department of Health and Human committee’s function. Every effort is Competitive Advantages: Services (HHS) is seeking nominations made to ensure that the views of all • Ease of manufacture for an individual to serve as a genders, all ethnic and racial groups, • Potent neutralizing activity nonfederal public member on the and people with disabilities are mstockstill on DSK3G9T082PROD with NOTICES • Potential cross-reactivity Muscular Dystrophy Coordinating • Low-cost therapeutics/ represented on HHS Federal advisory Committee. committees and, therefore, the immunoprophylaxis DATES: Nominations are due by 5 p.m. Department encourages nominations of Development Stage: EST on March 17, 2017. qualified candidates from these groups. • In vivo data assessment (animal) ADDRESSES: Nominations must be sent The Department also encourages Inventors: Lisbeth Kim Green (NIAID), to Glen Nuckolls, Ph.D., by email to geographic diversity in the composition Karin Bok (NIAID), Stanislav nuckollg@ninds.nih.gov. of the Committee. Appointment to this VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1

10778 Federal Register / Vol. 82, No. 30 / Wednesday, February 15, 2017 / Notices Committee shall be made without published in the Federal Register on DEPARTMENT OF HEALTH AND discrimination on the basis of age, race, January 23, 2017, 82 FR 7842. HUMAN SERVICES ethnicity, gender, sexual orientation, The meeting will be held on 02/17/ disability, and cultural, religious, or National Institutes of Health 2017 instead of 02/16/2017–02/17/2017. socioeconomic status. Requests for The meeting time and location remains reasonable accommodation to enable National Institute of Allergy and the same. The meeting is closed to the Infectious Diseases; Notice of Closed participation on the Committee should public. Meeting be indicated in the nomination submission. Dated: February 9, 2017. Pursuant to section 10(d) of the Member Terms: Non-Federal public David Clary, Federal Advisory Committee Act, as members of the Committee serve for a Program Analyst, Office of Federal Advisory amended (5 U.S.C. App.), notice is term of 3 years, and may serve for an Committee Policy. hereby given of the following meeting. unlimited number of terms if [FR Doc. 2017–03013 Filed 2–14–17; 8:45 am] The meeting will be closed to the reappointed. Members may serve after BILLING CODE 4140–01–P public in accordance with the the expiration of their terms, until their provisions set forth in sections successors have taken office. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Meetings and Travel: As specified by DEPARTMENT OF HEALTH AND as amended. The grant applications and Pub. L. 113–166, the MDCC ‘‘shall meet HUMAN SERVICES the discussions could disclose no fewer than two times per calendar confidential trade secrets or commercial year.’’ Travel expenses are provided for National Institutes of Health property such as patentable material, non-federal public Committee members and personal information concerning to facilitate attendance at in-person National Institute of Biomedical individuals associated with the grant meetings. Members are expected to Imaging and Bioengineering; Notice of applications, the disclosure of which make every effort to attend all full Closed Meeting would constitute a clearly unwarranted committee meetings, twice per year, invasion of personal privacy. either in person or via remote access. Pursuant to section 10(d) of the Name of Committee: Microbiology, Participation in relevant subcommittee, Federal Advisory Committee Act, as Infectious Diseases and AIDS Initial Review working and planning group meetings, amended (5 U.S.C. App.), notice is Group; Microbiology and Infectious Diseases and workshops, is also encouraged. hereby given of the following meeting. B Subcommittee MID–B March 2017. Date: March 6–7, 2017. Submission Instructions and The meeting will be closed to the Time: 8:00 a.m. to 5:00 p.m. Deadline: Nominations are due by 5 public in accordance with the Agenda: To review and evaluate grant p.m. EST on March 17, 2017, and provisions set forth in sections applications. should be sent to Glen Nuckolls, Ph.D., 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Place: Marriott Courtyard Gaithersburg by email to nuckollg@ninds.nih.gov. Washingtonian Center, 204 Boardwalk Place, as amended. The grant applications and Gaithersburg, MD 20878. Nominations must include contact the discussions could disclose information for the nominee, a current Contact Person: Ellen S. Buczko, Ph.D., confidential trade secrets or commercial Scientific Review Officer, Scientific Review curriculum vitae or resume of the Program, Division of Extramural Activities, property such as patentable material, nominee and a paragraph describing the National Institutes of Health/NIAID, 6700B and personal information concerning qualifications of the person to represent Rockledge Drive, MSC 7616, Bethesda, MD some portion(s) of the muscular individuals associated with the grant 20892–7616, 301–451–2676, ebuczko1@ dystrophy research, advocacy and/or applications, the disclosure of which niaid.nih.gov. patient care communities. would constitute a clearly unwarranted (Catalogue of Federal Domestic Assistance More information about the MDCC is invasion of personal privacy. Program Nos. 93.855, Allergy, Immunology, available at https://mdcc.nih.gov/. Name of Committee: National Institute of and Transplantation Research; 93.856, Microbiology and Infectious Diseases Dated: February 10, 2017. Biomedical Imaging and Bioengineering Research, National Institutes of Health, HHS) Special Emphasis Panel; K Award—R13 Walter J. Koroshetz, Dated: February 9, 2017. Review Meeting (2017/05). Director, National Institute of Neurological Date: March 9, 2017. Natasha M. Copeland, Disorders and Stroke, National Institutes of Time: 10:00 a.m. to 6:00 p.m. Program Analyst, Office of Federal Advisory Health. Agenda: To review and evaluate grant Committee Policy. [FR Doc. 2017–03018 Filed 2–14–17; 8:45 am] applications. [FR Doc. 2017–03014 Filed 2–14–17; 8:45 am] BILLING CODE 4140–01–P Place: National Institutes of Health, Two BILLING CODE 4140–01–P Democracy Plaza, Suite 920, 6707 Democracy Boulevard, Bethesda, MD 20892 (Virtual DEPARTMENT OF HEALTH AND Meeting). DEPARTMENT OF HEALTH AND HUMAN SERVICES Contact Person: John K. Hayes, Ph.D., HUMAN SERVICES Scientific Review Officer, 6707 Democracy National Institutes of Health National Institutes of Health Boulevard, Suite 959, Democracy Two, Center for Scientific Review; Amended Bethesda, MD 20892, (301) 451–3398, hayesj@mail.nih.gov. Government-Owned Inventions; Notice of Meeting Availability for Licensing mstockstill on DSK3G9T082PROD with NOTICES Dated: February 9, 2017. Notice is hereby given of a change in AGENCY: National Institutes of Health, David Clary, the meeting of the Genetic Variation and HHS. Evolution Study Section, February 16, Program Analyst, Office of Federal Advisory Committee Policy. ACTION: Notice. 2017, 08:00 a.m. to February 17, 2017, 07:00 p.m., Renaissance M Street Hotel, [FR Doc. 2017–03012 Filed 2–14–17; 8:45 am] SUMMARY: The invention listed below is 1143 New Hampshire Avenue NW., BILLING CODE 4140–01–P owned by an agency of the U.S. Washington, DC 20037 which was Government and is available for VerDate Sep<11>2014 18:44 Feb 14, 2017 Jkt 241001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\15FEN1.SGM 15FEN1


Document Created: 2017-02-15 00:55:00
Document Modified: 2017-02-15 00:55:00
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesNominations are due by 5 p.m. EST on March 17, 2017.
ContactGlen Nuckolls, Ph.D., by email to [email protected]
FR Citation82 FR 10777 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR